Previous 10 | Next 10 |
Gainers: Creative Medical Technology (NASDAQ:CELZ) +33%. HOOKIPA Pharma (NASDAQ:HOOK) +18%. Zynex ZYXI +17%. AMN Healthcare Services (NYSE:AMN) +15%. ShockWave Medical (NASDAQ:SWAV) +10%. Losers: Baudax Bio (NASDAQ:BXRX) -11%. Nuvectis Pharma (NASDAQ:NVCT)...
Equillium (NASDAQ:EQ) acquired Bioniz Therapeutics, granting EQ exclusive worldwide rights to all current and future Bioniz products. The consideration is comprised of an all-stock upfront payment of ~5.7M unregistered EQ shares issuable to Bioniz stockholders, which represents ~19.3% of Equi...
Acquisition includes two first-in-class clinical-stage assets and proprietary product discovery platform Creates a robust immunology pipeline with significant value-creating milestones, and provides a strong clinical and research team with complementary expertise in immuno...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced timing updates for two separate conference presentations. Equillium will now participate in ...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will participate in a fireside chat presentation at the SVB Leerink Virtual Global Healt...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that three abstracts were accepted for presentation at the Transplantation & Cellular Me...
First data to demonstrate the contribution of CD6-ALCAM and T-cells to the pathogenesis of lupus nephritis Largest, most comprehensive cohort of lupus nephritis patients analy z ed to date supports soluble ALCAM as a biomarker for disease activity Equillium, Inc....
Study achieved primary objective of safety and tolerability Itolizumab demonstrated rapid and sustained reduction in levels of cell surface CD6 Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and i...
Data from EQUATE study continues to show rapid and durable complete responses, resulting in clinically meaningful reduction in corticosteroid use 79% of responders maintained or achieved a complete response at six months Pivotal study in aGVHD to commence in early ...
Equillium (NASDAQ:EQ): Q3 GAAP EPS of -$0.35 misses by $0.01. Revenue of $0M Press Release Cash, cash equivalents and short-term investments totaled $90.7 million as of September 30, 2021. For further details see: Equillium EPS misses by $0.01
News, Short Squeeze, Breakout and More Instantly...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will be participating in the Leerink Partners Therapeutic Forum: I&I and Metabolism, as well as the Jone...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it expects to join the Russell Microcap Index at the conclusion of the 2024 Russell annual reconstitution, effe...
A look at the top 10 most actives in the United States SOBR Safe Inc. (SOBR) rose 74.6% to $0.46 on volume of 265,324,361 shares MicroAlgo Inc. (MLGO) rose 669.9% to $12.01 on volume of 183,977,846 shares PROSHARES TRUST (SQQQ) fell 0.7% to $9.86 on volume of 124,114,596 shares Faraday ...